Trial Profile
A Phase 1/2 Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Feb 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Lirilumab (Primary) ; Nivolumab (Primary)
- Indications Head and neck cancer; Malignant melanoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 16 Mar 2020 Status changed from active, no longer recruiting to completed.
- 19 Jan 2020 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 05 Dec 2019 This trial has been completed in Italy, according to European Clinical Trials Database record.